Oriental Medicine Research Center for Bone & Joint, Disease Kyung Hee University, 149, Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea.
J Ethnopharmacol. 2011 Sep 2;137(2):1011-7. doi: 10.1016/j.jep.2011.07.025. Epub 2011 Jul 18.
The dried flowers of Lonicera japonica, also known as Japanese honeysuckle, and the dried root of Anemarrhena asphodeloides, the component herbs of WIN-34B, are traditionally used in Eastern medicine to treat various inflammatory conditions including arthritis.
To study the acute and chronic toxicities of WIN-34B and to compare its effects on gastric mucosa with those of diclofenac, a widely used NSAID, and celecoxib, a selective COX-2 inhibitor.
To investigate acute toxicity, we orally administered a single dose of 5,000 mg/kg WIN-34B to rats. To investigate chronic toxicity, we orally administered 500, 1000 or 2,000 mg/kg WIN-34B to rats daily for 13 weeks. To assess its effects on gastric mucosa, rats received either a single dose or repeated doses of WIN-34B (400, 1000, or 2,000 mg/kg), diclofenac (10, 40, or 80 mg/kg), celecoxib (100 or 1,000 mg/kg), or vehicle, after which samples of gastric mucosa were assessed grossly and histologically. We also measured tissue activity of myeloperoxidase and synthesis of eicosanoids, including prostaglandin E(2) (PGE(2)) and leukotriene B(4) (LTB(4)). To further assess its effects, we administered WIN-34B to rats either intraperitoneally or orally, measured gastric injury scores using a rat model of diclofenac-induced gastric injury, and measured eicosanoid synthesis.
WIN-34B showed no signs of acute or chronic toxicity in terms of general behavior, gross appearance of the internal organs, blood chemistry, or mortality. WIN-34B did not cause significant gastric mucosal damage after single or repeated doses. In contrast, diclofenac and celecoxib both caused gastric damage. In terms of eicosanoid synthesis, WIN-34B significantly suppressed LTB(4) synthesis while both diclofenac and celecoxib increased LTB(4) synthesis. WIN-34B slightly reduced PGE(2) production, while both diclofenac and celecoxib significantly reduced PGE(2) production. In a rat model of diclofenac-induced gastric injury, WIN-34B significantly suppressed LTB(4) synthesis and restored PGE(2) release.
These results demonstrate that WIN-34B did not cause acute or chronic toxicity in male or female rats. In addition, WIN-34B did not cause significant gastric mucosal damage, instead appearing to protect the mucosa from diclofenac-induced gastric damage through the regulation of PGE(2) and LTB(4).
金银花的干花,也被称为忍冬,以及知母的干根,WIN-34B 的组成草药,在东方医学中传统上用于治疗各种炎症性疾病,包括关节炎。
研究 WIN-34B 的急性和慢性毒性,并将其对胃黏膜的影响与广泛使用的非甾体抗炎药(NSAID)双氯芬酸和选择性 COX-2 抑制剂塞来昔布进行比较。
为了研究急性毒性,我们给大鼠口服 5,000 mg/kg 的 WIN-34B 单剂量。为了研究慢性毒性,我们每天给大鼠口服 500、1000 或 2,000 mg/kg 的 WIN-34B,为期 13 周。为了评估其对胃黏膜的影响,大鼠接受单次或重复剂量的 WIN-34B(400、1000 或 2,000 mg/kg)、双氯芬酸(10、40 或 80 mg/kg)、塞来昔布(100 或 1,000 mg/kg)或载体,之后评估胃黏膜的大体和组织学变化。我们还测量了髓过氧化物酶的组织活性和前列腺素 E2(PGE2)和白三烯 B4(LTB4)等类二十烷酸的合成。为了进一步评估其作用,我们给大鼠腹腔内或口服给予 WIN-34B,使用双氯芬酸诱导的胃损伤大鼠模型测量胃损伤评分,并测量类二十烷酸的合成。
WIN-34B 在一般行为、内脏器官大体外观、血液化学或死亡率方面均未表现出急性或慢性毒性的迹象。WIN-34B 单次或重复剂量后均未引起明显的胃黏膜损伤。相比之下,双氯芬酸和塞来昔布均引起胃损伤。在类二十烷酸合成方面,WIN-34B 显著抑制 LTB4 合成,而双氯芬酸和塞来昔布均增加 LTB4 合成。WIN-34B 轻度减少 PGE2 的产生,而双氯芬酸和塞来昔布则显著减少 PGE2 的产生。在双氯芬酸诱导的胃损伤大鼠模型中,WIN-34B 显著抑制 LTB4 合成并恢复 PGE2 的释放。
这些结果表明 WIN-34B 未引起雄性或雌性大鼠的急性或慢性毒性。此外,WIN-34B 未引起明显的胃黏膜损伤,反而通过调节 PGE2 和 LTB4 似乎保护胃黏膜免受双氯芬酸引起的胃损伤。